Hematology Branch
Our Labs
Hematopoiesis and Bone Marrow Failure
Research in the Hematopoiesis and Bone Marrow Failure Laboratory, led by Dr. Neal Young, spans the basic sciences, clinical trials, and epidemiology. Bench work involves methods of cell and molecular biology, immunology, and virology. Blood cell production in healthy individuals and especially in patients with bone marrow failure is the main theme. Advanced techniques most recently include single cell RNAseq, CRISPR-Cas9 gene editing, multicolored bar coded flow cytometry, and SomaLogic deep proteomics.
- Neal Young
- M.D.
- Senior Investigator
Lymphoid Malignancies
The Laboratory of Lymphoid Malignancies, led by Dr. Adrian Wiestner, aims to improve the treatment of patients with chronic lymphocytic leukemia (CLL). The group combines clinical and laboratory investigations to identify the molecular drivers of the disease. These insights are translated into clinical trials that seek to selectively eliminate tumor cells using targeted therapy. CLL samples donated by patients participating in these clinical trials are in turn used in the laboratory to study the effectiveness of the treatment and the reaction of the tumor cells to drugs, which can provide insights how to further improve the therapy.
- Adrian Wiestner
- M.D., Ph.D.
- Senior Investigator
Molecular Hematopoiesis
Research in the Laboratory of Molecular Hematopoiesis, led by Dr. Cynthia E. Dunbar, focuses on understanding the process of hematopoiesis in humans and in animal models that closely predict biology and disease in humans.
- Cynthia "Cindy" Dunbar
- M.D.
- Scientist Emeritus
Hematology Consult Service and Hematology Oncology Fellowship Program
The Hematology Consult Service provides consultative hematology care to patients throughout the 200-bed Clinical Center and the associated outpatient clinics. This service can provide expertise in a broad spectrum of hematologic problems, with an emphasis on hemostasis and coagulation; cytopenias associate with HIV infection and other immunologic abnormalities; hematology complications of novel drug therapies; and hematologic manifestations of a diverse collection of rare diseases.
The Hematology Oncology Fellowship uses the unique clinical and basic research resources of the NIH to advance the diagnosis, treatment, and prevention of hematologic and oncologic diseases by developing and training the next generation of clinicians and physician scientists. This program is jointly sponsored by the National Cancer Institute and National Heart, Lung, and Blood Institute.
- Charles Bolan
- M.D.
- Director